Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Social media has largely overshadowed the investing fundamentals with pumpamentals, spotlighting meme stocks to sell. Just as Bitcoin is analog to blue-chip stocks, meme stocks have similarly become analog to altcoins. Both are driven by narratives fed by short-term valuation surges. But, just as easily as they went up, meme stocks can go down. Pitting their float shorted against dwindling revenue figures and rapid cash depletion, which meme stocks should be ousted from your speculative portfoli
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday,
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript March 14, 2024 Allogene Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2023 Conference […]
Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.
Q4 2023 Allogene Therapeutics Inc Earnings Call
2024 Financial Guidance: Anticipates a decrease in cash, cash equivalents, and investments of approximately $190 million, with GAAP Operating Expenses around $280 million. On March 14, 2024, Allogene Therapeutics Inc (NASDAQ:ALLO) released its 8-K filing, detailing the company's financial results for the fourth quarter and the full year of 2023. Allogene, a clinical-stage immuno-oncology company, is at the forefront of developing allogeneic T cell therapies for cancer treatment, with a focus o...
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 8.51% and 54.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL): Start-Up Activities Underway; Enrollment to Begin Mid-2024Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Data Projected YE 2024ALLO-329 in Autoimmune Disease (AID): Differentiated Next-Generation CD19 Dagger® Program Designed for AID will Focus on Eliminating Lymphodepletion and Meeting Demand; Phase 1 Clinical Trials in Early 2025